FDA Expands Tzield Use to Younger Children with Type 1 Diabetes
The U.S. Food and Drug Administration has approved an expanded indication for Tzield (teplizumab-mzwv), allowing its use in children as young as one year old to delay the onset of stage…
Read More...
Read More...
